2-Chlorodeoxyadenosine: A New Nucleoside Agent Effective in the Treatment of Lymphoid Malignancies

This publication has 19 references indexed in Scilit:

• Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine.
  Proceedings of the National Academy of Sciences, 1992
• A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia.
  Journal of Clinical Oncology, 1991
• 2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic Leukemia
  Leukemia & Lymphoma, 1991
• Lasting Remissions in Hairy-Cell Leukemia Induced by a Single Infusion of 2-Chlorodeoxyadenosine
  New England Journal of Medicine, 1990
• Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group
  American Journal of Hematology, 1988
• Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.
  Journal of Clinical Investigation, 1985
• Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine.
  Proceedings of the National Academy of Sciences, 1984
• Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes
  Blood, 1983
• Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.
  Proceedings of the National Academy of Sciences, 1980
• ADENOSINE-DEAMINASE DEFICIENCY IN TWO PATIENTS WITH SEVERELY IMPAIRED CELLULAR IMMUNITY
  The Lancet, 1972